BUSINESS
Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
By Reiji Anasako July 4, 2022
Chugai Pharmaceutical became the best-paying Japanese drug maker for the first time in FY2021 with an average annual pay of 11.56 million yen, according to securities filings tallied by Jiho. Four firms including the Roche group company topped the 10…

LATEST

July 4, 2022
The Institute for New Era Strategy (INES) said on June 30 that it has launched a study group on sustainable health finance and new sources of funding, with an eye to comprehensive discussions on the…
July 4, 2022
The Japan Agency for Medical Research and Development (AMED) said on June 30 that it has selected eight companies as certified venture capitals under its funding project to boost the country’s drug discovery ecosystem.Under the project, AMED will provide funding…
July 4, 2022
Japan has reported five new “probable” cases of children with acute hepatitis of unknown etiology, bringing the total number of such detections to 67, the Japanese health ministry said on July 1.According to the WHO’s tentative definition, a probable case…
By Izuru Ando

Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…

By Philip Carrigan

“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA